MAOB and Parkinson disease: The reversibility of the MAO-B inhibition of safinamide represents a clear advantage compared to the other MAO-B inhibitors when treating advanced PD patients with concomitant morbidities and high concomitant medications load, due to the reduced risk of drug interactions.